Gilead Sciences Get European Commission Grant For Marketing Authorization Of Its Single Tablet Regimen Odefsey

Gilead Sciences, Inc.

revealed the European Commission's approval for marketing authorization for the once-daily single tablet regimen (STR) Odefsey for the treatment of HIV-1 infection in some patients. According to the company, Odefsey integrates its emtricitabine and tenofovir alafenamide with rilpivirine, marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson

. Gilead said that after the Genvoya approval in November 2015, its Odefsey is the second STR based on the Descovy backbone to get marketing authorization in the European Union. The company claimed that it was the smallest pill of any STR for the treatment of HIV currently. The company's EVP, R&D, and Chief Scientific Officer, Norbert Bischofberger, said, "The approval of Odefsey underscores Gilead's ongoing commitment to researching and developing new treatment options to help address the evolving needs of a range of HIV patients. Through our new portfolio of products based on the Descovy backbone, Gilead is pleased to offer effective treatments and simple dosing options for people living with HIV, which has now become a chronic condition for most patients." The drug made said that Odefsey was indicated for the treatment of adults and adolescents in the European Union. The drug, Odefsey, aligns the antiviral efficacy and safety profile of the new Descovy backbone with the established tolerability profile of rilpivirine as a third agent. On Thursday, the stock traded 0.6 percent up.